Small cell lung cancer accounts for 15% to 20% of all lung cancers and is gradually decreasing in proportion to lung cancer. Small cell lung cancer is very sensitive to initial chemotherapy and radiation therapy, but it mostly recurs more quickly. Staging: Small cell lung cancer is divided into limited stage and extensive stage. Limited stage means the tumor is located in one side of the chest cavity and can be safely treated with radiotherapy within one radiation field. Beyond these ranges is extensive stage small cell lung cancer, which includes malignant pleural effusion, malignant pericardial effusion, superior vena cava compression syndrome, and those with extrathoracic dissemination. The consensus for the treatment of limited-stage small cell lung cancer is that the combination of systemic chemotherapy and chest radiotherapy can prolong patient survival; early radiotherapy is more effective than late radiotherapy; chemotherapy regimens in combination with radiotherapy are recommended for pedialyte glycosides in combination with cisplatin; and prophylactic brain radiotherapy is recommended for patients in complete remission after treatment. Treatment of extensive stage small cell lung cancer: systemic chemotherapy is the main treatment, and the recommended chemotherapy regimen is pegylated glycosides in combination with cisplatin or pegylated glycosides in combination with carboplatin. Patients do not benefit from more than 6 cycles of continuous chemotherapy. Other options include CAV regimen, Kepto combined with cisplatin regimen, and Hormexin combined with cisplatin regimen. Second-line treatment for small cell lung cancer: small cell lung cancer that recurs within 3 months after treatment can be treated with non-small cell lung cancer regimens; those that recur between 3 and 6 months can choose the Hormexin regimen or the Kepto regimen as well as the CAV regimen; those that recur more than 6 months later can receive the original regimen. The key points for successful treatment of small cell lung cancer: clear pathological diagnosis, accurate staging, early involvement of radiation therapy for limited stage small cell lung cancer, etc.